Cargando…
Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361276/ https://www.ncbi.nlm.nih.gov/pubmed/16641905 http://dx.doi.org/10.1038/sj.bjc.6603114 |
| _version_ | 1782153176654282752 |
|---|---|
| author | Banna, G L Aversa, S M L Crivellari, G Ghiotto, C Chiarion-Sileni, V Monfardini, S |
| author_facet | Banna, G L Aversa, S M L Crivellari, G Ghiotto, C Chiarion-Sileni, V Monfardini, S |
| author_sort | Banna, G L |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2361276 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2006 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23612762009-09-10 Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer Banna, G L Aversa, S M L Crivellari, G Ghiotto, C Chiarion-Sileni, V Monfardini, S Br J Cancer Letter to the Editor Nature Publishing Group 2006-05-22 2006-04-25 /pmc/articles/PMC2361276/ /pubmed/16641905 http://dx.doi.org/10.1038/sj.bjc.6603114 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Banna, G L Aversa, S M L Crivellari, G Ghiotto, C Chiarion-Sileni, V Monfardini, S Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| title | Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| title_full | Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| title_fullStr | Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| title_full_unstemmed | Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| title_short | Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| title_sort | administration of anti-her2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361276/ https://www.ncbi.nlm.nih.gov/pubmed/16641905 http://dx.doi.org/10.1038/sj.bjc.6603114 |
| work_keys_str_mv | AT bannagl administrationofantiher2antibodyafternonmyeloablativeallogeneicstemcelltransplantationinmetastaticbreastcancer AT aversasml administrationofantiher2antibodyafternonmyeloablativeallogeneicstemcelltransplantationinmetastaticbreastcancer AT crivellarig administrationofantiher2antibodyafternonmyeloablativeallogeneicstemcelltransplantationinmetastaticbreastcancer AT ghiottoc administrationofantiher2antibodyafternonmyeloablativeallogeneicstemcelltransplantationinmetastaticbreastcancer AT chiarionsileniv administrationofantiher2antibodyafternonmyeloablativeallogeneicstemcelltransplantationinmetastaticbreastcancer AT monfardinis administrationofantiher2antibodyafternonmyeloablativeallogeneicstemcelltransplantationinmetastaticbreastcancer |